logo-loader

Zelira Therapeutics has clinical trial results of Zenivol® published in SLEEP®

Published: 22:03 20 Jun 2021 EDT

Zelira Therapeutics Ltd - Zelira Therapeutics has clinical trial results of Zenivol® published in SLEEP®
Zelira’s proprietary Zenivol formulation was launched in Australia in September 2020.

Zelira Therapeutics Ltd (ASX:ZLD) (OTCMKTS:ZLDAF) (FRA:G1G) is encouraged that the results of a trial in chronic insomnia patients of its proprietary cannabinoid ZLT101 formulation marketed as Zenivol® have been published in the peer-reviewed journal SLEEP®.

The double-blind, placebo-controlled, cross-over trial was carried out by the University of Western Australia’s investigational team.

First announced in February 2020, the results of this trial were the world’s first clinically validated cannabis formulation for treating insomnia.

Zelira continues to lead the world in creating and validating proprietary medicinal cannabis products such as Zenivol with a focus on taking these drugs through regulatory registration.

Higher level of confidence

The company’s managing director Oludare Odumosu said: “Physicians and patients often ask for published peer-reviewed data from a double-blind, placebo-controlled, cross-over study.

“With this publication in the prestigious and high impact journal of SLEEP of the results from the University of Western Australia’s trial, we can confidently say ‘here you have the first scientific peer-reviewed publication for a cannabinoid medicine to treat insomnia’.

“Now, prescribers will have a higher level of confidence in using Zelira’s Zenivol to treat their patients battling chronic insomnia.

“Zelira is committed to taking Zenivol through registration approval as the worlds’ first fully validated and approved cannabinoid treatment for chronic insomnia.”

SLEEP journal

SLEEP, the official publication of the Sleep Research Society, is the benchmark international journal for all sleep-related conditions with a mission to publish innovative, high-impact research findings across the basic, translational, and clinical research spectrum.

Publication in the prestigious SLEEP journal provides the foremost evidence-based, peer-reviewed clinical trial data for doctors who treat patients with chronic insomnia.

The trial

The trial was undertaken at the world-class University of Western Australia Centre for Sleep Science and was led by principal investigator Professor Peter Eastwood with Jennifer Walsh as the corresponding author.

Zelira first announced the positive Phase 1b/2a results on February 19, 2020, and provided additional detail on the primary and secondary endpoints achieved on April 7, 2020.

The proprietary Zenivol formulation was launched in Australia in September 2020 and is available to prescribers and patients through the Therapeutic Goods Administrations (TGA) Special Access and Authorised Prescriber Schemes.

Lead author Jennifer Walsh said: “The results demonstrate significant improvements in a number of important insomnia metrics which is encouraging preliminary evidence that ZTL-101, Zelira’s Zenivol, has potential to treat this highly prevalent condition.”

BenevolentAI advances novel ulcerative colitis treatment through Phase 1a trial

BenevolentAI (OTC:BAIVF) chief scientific officer Dr Anne Phelan joins Proactive's Stephen Gunnion with positive safety data from the Phase 1a, first-in-human, clinical study of BEN-8744 in healthy volunteers. Phelan explained that BEN-8744 is a potent, selective PD10 inhibitor, uniquely...

2 hours ago